Overview
This is a double-blind, placebo-controlled, randomized withdrawal, multicenter study of the efficacy and safety of FT218. FT218 drug product is a once-nightly formulation of sodium oxybate for extended-release oral suspension. The study will enroll subjects who are diagnosed with idiopathic hypersomnia. Subjects will be eligible to enroll regardless of current treatment with oxybate therapy or stimulants/alerting agents at study entry. The estimated total duration of study for each subject is approximately 18 weeks, including the Screening period.
Eligibility
Inclusion Criteria:
- Primary diagnosis of idiopathic hypersomnia
- Total ESS score at Screening > 11 if not on prior oxybate
- Average nightly total sleep time of > 7 hours
- May use stimulants/alerting agents but dose and regimen must have been stable for 2 months prior to Screening, and remain stable until the double-blind, randomized withdrawal visit
- Females of childbearing potential must use highly effective contraception for 2 months prior to Baseline, throughout the study, and for 30 days after the last dose of study drug
- Males with female partners of childbearing potential must use condoms throughout the study and for 30 days after the last dose of study drug
- Willing and able to provide informed consent and comply with the requirements of the study
Exclusion Criteria:
- Pregnant, nursing or lactating females
- Hypersomnia due to another medical, behavioral, sleep, or psychiatric condition
- Untreated or incompletely treated sleep apnea in patients with an apnea-hypopnea index (AHI) ≥ 15 by American Academy of Sleep Medicine (AASM) 1A criteria
- Clinically significant parasomnias
- History or presence of seizures, head trauma, succinic semialdehyde dehydrogenase deficiency, uncontrolled hypothyroidism, and/or significant hepatic impairment
- History or presence of bipolar and related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders
- Ongoing or past (within 1 year) major depressive episode
- At risk for suicide or history of suicide attempt
- If not on oxybate at Screening, treatment or planned treatment with any central nervous system (CNS) sedating agents during study
- Current or past substance use disorder (including alcohol or cannabinoids)
- Excessive caffeine consumption (> 600 mg/day)
- Prior treatment with either FT218 or LUMRYZ